Department of Internal Medicine and Paediatrics, Ghent University and Paediatric Endocrinology Service, Department of Paediatrics, Ghent University Hospital, Ghent, Belgium.
Vereniging voor Intersekse Personen VZW/Association for Intersex People (NGO), Meise, Belgium.
Clin Endocrinol (Oxf). 2024 Nov;101(5):499-506. doi: 10.1111/cen.15002. Epub 2023 Dec 7.
Medical treatments that aim to modify the appearance of the genitals in children who are born with a difference of sex development/intersex (DSD/I*) condition are highly controversial. Human Rights bodies worldwide have argued that such treatments are conflicting with the child's right of personal autonomy and should be legally restricted to the unique situation where the child's physical health is in danger.
We here review the current status of legal initiatives in Europe that have addressed the issue of medical treatments in minors who have a DSD for which they have not been able to give personal informed consent due to their young age.
The management of a 3 years old child who has congenital adrenal hyperplasia (CAH) and grows up with atypical-looking genitals is discussed.
In spite of extensive psychosocial support to the child and family from birth onwards, and good medical control of CAH, the child develops signs of emotional distress, suspected to be attributable to the genital difference. Our discussions include perspectives from the multidisciplinary DSD team caring for the child, a human rights specialist, and an intersex activist. From our discussions, we conclude that with evolving medical care, new ethical and human rights challenges are raised. A truly holistic human rights approach should not only consider physical but also mental health and psychosocial and psychosexual adaptation of the child to the medical condition, when reflecting on the acceptability of medical treatments in minors for which no personal informed consent can be obtained due to their young age. In addition it is paramount to include the meaningful participation of the child in the clinical management at the earliest possible stage.
Continued convergence of clinical management and the human rights framework can be realised based on constructive discussions involving all stakeholders, and with the best interest of the child - and adult that they will become - as a common goal.
旨在改变患有性别发育障碍/性器官发育异常(DSD/I*)儿童生殖器外观的医疗方法极具争议性。世界各地的人权机构认为,此类治疗方法与儿童的个人自主权相冲突,应在法律上仅限于儿童身体健康受到威胁的特殊情况下进行限制。
我们在此回顾了欧洲目前在处理因未成年而无法给予个人知情同意的 DSD 未成年人医疗方法的法律举措。
讨论了一名患有先天性肾上腺增生症(CAH)的 3 岁儿童的管理问题。这名儿童的生殖器外观异常。
尽管从出生开始就为儿童及其家庭提供了广泛的社会心理支持,并对 CAH 进行了良好的医疗控制,但儿童还是出现了情绪困扰的迹象,疑似与生殖器差异有关。我们的讨论包括照顾儿童的多学科 DSD 团队、人权专家和跨性别活动家的观点。从讨论中,我们得出结论,随着医疗护理的发展,新的伦理和人权挑战也随之出现。真正的整体人权方法不仅应考虑身体,还应考虑儿童的心理健康以及他们对医疗状况的心理社会和性适应,当反思因未成年而无法获得个人知情同意的未成年人医疗方法的可接受性时,这一点至关重要。此外,至关重要的是要让儿童尽早在临床管理中真正参与进来。
继续通过涉及所有利益相关者的建设性讨论,以儿童——以及他们将来会成为的成年人——的最佳利益为共同目标,可以实现临床管理和人权框架的融合。